BioNexus Gene Lab Corp (BGLC) · Oct 7, 2026 · Material agreement
$3.5M license — 10-year exclusive Malaysia healthcare licence for 410,000 shares plus 10% royalties
BioNexus Gene Lab signed a 10-year Malaysia healthcare AI license with RYET, paying in 560,000 shares plus a 10% royalty.
BGLC is adding healthcare AI to a Malaysia-centered diagnostics platform. BioNexus operates Malaysian laboratory businesses and has been broadening beyond genomic testing into healthcare technology; RYET, meanwhile, is repositioning Cogni AI from document recognition toward private-deployment institutional and enterprise systems, with Formind Global intended as its Malaysia-based international platform.
The agreement gives BGLC a real product and local exclusivity, not merely a partnership announcement. BGLC receives a 10-year licence to deploy, adapt, brand and sublicense CogniAI across Malaysian healthcare, with exclusivity for the term. 〔0〕 The licence covers hospitals, clinics, laboratories, patient records, healthcare administration and EHR connectivity, giving BGLC a defined platform for its healthcare-AI expansion rather than requiring it to build document intelligence from scratch.
The price is substantial equity plus a continuing revenue share, while preserving flexibility. BGLC pays the agreed US$3.5 million licence consideration in 410,000 shares and issues another 150,000 shares for the reciprocal investment. 〔1〕 〔2〕 There is no cash licence payment, annual fee or minimum volume, but BGLC must pay RYET 10% of collected customer receipts. 〔3〕 Based on BGLC's 2,417,314 shares outstanding at June 30, 2026, the 560,000-share issuance would represent roughly 23% additional shares before any other changes.
The commercial upside is still only an option, because the filing contains no customer, revenue or government award. BGLC can sell projects without RYET approval and keeps customer revenue net of the royalty, but the agreement does not guarantee business volume. RYET's recent Cogni AI expansion shows the platform has been commercialized in archives and infrastructure records, yet that is not proof of healthcare adoption or Malaysian procurement.
Execution is gated by delivery, acceptance and closing. RYET must deliver the software, documentation and training; BGLC can terminate if the technology fails a second acceptance test, and either party can terminate if closing has not occurred by March 31, 2027. 〔4〕 〔5〕 The Malaysia-only data-hosting and access rules also make the arrangement more suitable for regulated healthcare, but potentially more operationally demanding.
Bottom line: This materially advances BGLC's healthcare-AI buildout by securing an exclusive platform without an upfront cash outlay, but it is not yet commercial traction. The dilution and 10% royalty are immediate economic costs; the payoff depends on BGLC converting the licence into signed healthcare deployments before closing and afterward.
Closing and acceptance testing, no later than March 31, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!